JP2011510327A5 - - Google Patents

Download PDF

Info

Publication number
JP2011510327A5
JP2011510327A5 JP2010544349A JP2010544349A JP2011510327A5 JP 2011510327 A5 JP2011510327 A5 JP 2011510327A5 JP 2010544349 A JP2010544349 A JP 2010544349A JP 2010544349 A JP2010544349 A JP 2010544349A JP 2011510327 A5 JP2011510327 A5 JP 2011510327A5
Authority
JP
Japan
Prior art keywords
predetermined value
subject
gelsolin
plasma
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010544349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011510327A (ja
JP5778425B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/000452 external-priority patent/WO2009094194A2/en
Publication of JP2011510327A publication Critical patent/JP2011510327A/ja
Publication of JP2011510327A5 publication Critical patent/JP2011510327A5/ja
Application granted granted Critical
Publication of JP5778425B2 publication Critical patent/JP5778425B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010544349A 2008-01-25 2009-01-23 腎不全におけるゲルソリンの診断的および治療的使用 Active JP5778425B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2378908P 2008-01-25 2008-01-25
US61/023,789 2008-01-25
PCT/US2009/000452 WO2009094194A2 (en) 2008-01-25 2009-01-23 Diagnostic and therapeutic uses of gelsolin in renal failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015005994A Division JP6042915B2 (ja) 2008-01-25 2015-01-15 腎不全におけるゲルソリンの診断的および治療的使用

Publications (3)

Publication Number Publication Date
JP2011510327A JP2011510327A (ja) 2011-03-31
JP2011510327A5 true JP2011510327A5 (cg-RX-API-DMAC7.html) 2013-08-29
JP5778425B2 JP5778425B2 (ja) 2015-09-16

Family

ID=40901583

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010544349A Active JP5778425B2 (ja) 2008-01-25 2009-01-23 腎不全におけるゲルソリンの診断的および治療的使用
JP2015005994A Active JP6042915B2 (ja) 2008-01-25 2015-01-15 腎不全におけるゲルソリンの診断的および治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015005994A Active JP6042915B2 (ja) 2008-01-25 2015-01-15 腎不全におけるゲルソリンの診断的および治療的使用

Country Status (10)

Country Link
US (2) US9575072B2 (cg-RX-API-DMAC7.html)
EP (2) EP2708603B1 (cg-RX-API-DMAC7.html)
JP (2) JP5778425B2 (cg-RX-API-DMAC7.html)
CA (2) CA2749985C (cg-RX-API-DMAC7.html)
DK (2) DK2708603T3 (cg-RX-API-DMAC7.html)
ES (2) ES2531827T3 (cg-RX-API-DMAC7.html)
HU (1) HUE032875T2 (cg-RX-API-DMAC7.html)
PL (2) PL2708603T3 (cg-RX-API-DMAC7.html)
PT (2) PT2250280E (cg-RX-API-DMAC7.html)
WO (1) WO2009094194A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1694342T3 (da) * 2003-11-12 2021-02-08 Univ Pennsylvania Fremgangsmåder til anvendelse af gelsolin til behandling eller forebyggelse af bakteriel sepsis
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
KR101300929B1 (ko) * 2004-05-12 2013-08-27 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
HUE056086T2 (hu) 2006-03-15 2022-01-28 Brigham & Womens Hospital Inc Gelszolin alkalmazása gyulladásos betegségek diagnosztizálására és kezelésére
PT2002258T (pt) * 2006-03-15 2017-12-18 The Brigham And Women`S Hospital Inc Utilização de gelsolina para o tratamento da esclerose múltipla e para o diagnóstico de doenças neurológicas
EP2535718B1 (en) 2007-05-11 2014-07-09 The Institutes for Pharmaceutical Discovery, LLC Methods for early diagnosis of kidney disease
PT2250280E (pt) 2008-01-25 2015-03-04 Gen Hospital Corp Utilizações terapêuticas da gelsolina na insuficiência renal
WO2010025128A1 (en) * 2008-08-25 2010-03-04 Critical Biologics Corporation Methods for reducing sample size of clinical trials
ES2356217B1 (es) * 2009-08-04 2012-02-13 Universidad De Salamanca Método para la detección de daño renal.
TW201601741A (zh) * 2013-09-09 2016-01-16 品特生物療法有限公司 用於治療esrd病患之pew的肌肉生長抑制素拮抗劑
CN104004780A (zh) * 2014-06-17 2014-08-27 南京大学 一种人胞质凝溶胶蛋白的表达纯化方法
WO2016033187A1 (en) * 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease
JP6947449B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
JP7713892B2 (ja) * 2019-06-21 2025-07-28 バイオイージス・セラピューティクス・インコーポレーテッド 感染を処置するための組成物および相乗的方法
WO2021225937A1 (en) * 2020-05-04 2021-11-11 Bioaegis Therapeutics Inc. Compositions comprising gelsolin for treating frailty

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
CA2016227A1 (en) * 1989-05-18 1990-11-18 Xandra O. Breakefield Genetic diagnosis of torsion dystonia
AU663050B2 (en) * 1990-04-11 1995-09-28 Brigham And Women's Hospital Therapeutic uses of actin-binding compounds
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
CA2063593A1 (en) 1990-05-04 1991-11-05 R. Blake Pepinsky Multimeric gelsolin fusion constructs
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
CA2082951C (en) 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
US5360350A (en) * 1991-08-23 1994-11-01 The Whitaker Corporation Sealant compositions and sealed electrical connectors
CA2141600A1 (en) 1992-08-03 1994-02-17 Richard U. Margolis Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
WO1994008049A1 (en) 1992-10-01 1994-04-14 The General Hospital Corporation Functional assay for tumor suppressor genes
US5830436A (en) 1993-03-30 1998-11-03 Duke University Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
US5593964A (en) 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
JP3914272B2 (ja) * 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5563153A (en) 1995-02-22 1996-10-08 University Of Kansas Medical Center Sterile topical anesthetic gel
US5846743A (en) * 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5804427A (en) * 1995-05-19 1998-09-08 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US5925529A (en) * 1995-06-07 1999-07-20 The Regents Of The University Of California Method for discovery of peptide agonists
US5569588A (en) * 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5750353A (en) * 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
AU3817497A (en) 1996-07-30 1998-02-20 Biogen, Inc. Production of recombinant plasma gelsolin containing a disulfide bond
AU744750B2 (en) * 1996-12-04 2002-02-28 Renovo Limited Wound healing and treatment of fibrosis
PT1493439E (pt) * 1997-04-02 2012-01-10 Brigham & Womens Hospital Meio de avaliação do perfil de risco de um indivíduo para uma doença aterosclerótica
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2001024828A2 (en) 1999-10-06 2001-04-12 Basf Aktiengesellschaft MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN αVβ3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY
WO2002059604A2 (en) 2001-01-26 2002-08-01 Oxford Glycosciences (Uk) Ltd Diagnosis and treatment of multiple sclerosis
MXPA03007878A (es) 2001-03-02 2004-07-08 Medimmune Inc Metodos de prevencion o tratamiento de alteraciones inflamatorias o autoinmunes mediante la administracion de los antagonistas alfav, beta3 de integrina.
EP1249244A1 (en) * 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
DE60233414D1 (de) 2001-07-09 2009-10-01 Combinatorx Inc Kombinationen für die behandlung entzündlicher erkrankungen
WO2003020213A2 (en) 2001-08-30 2003-03-13 Praecis Pharmaceuticals Incorporated Methods and compositions for treating inflammatory disorders
US20060089310A1 (en) 2002-02-06 2006-04-27 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
US20080051348A1 (en) 2002-02-06 2008-02-28 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
WO2003088811A2 (en) 2002-04-16 2003-10-30 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
AU2003253014A1 (en) * 2002-06-21 2004-01-06 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
WO2004082617A2 (en) 2003-03-14 2004-09-30 Ppd Biomarker Discovery Sciences, Llc Biological markers for diagnosing rheumatoid arthritis
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
DK1694342T3 (da) * 2003-11-12 2021-02-08 Univ Pennsylvania Fremgangsmåder til anvendelse af gelsolin til behandling eller forebyggelse af bakteriel sepsis
CA2550833A1 (en) 2003-12-22 2005-07-14 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
ES2541683T3 (es) 2004-02-27 2015-07-23 F. Hoffmann-La Roche Ag Método para evaluar la artritis reumatoide mediante la medición del factor reumatoide y la interleuquina-6
KR101300929B1 (ko) 2004-05-12 2013-08-27 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
EP1753455A2 (en) 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
US20100062471A1 (en) 2005-09-29 2010-03-11 Ppd Biomarker Discovery Sciences Llc Biomarkers for Multiple Sclerosis and Methods of Use Thereof
PT2002258T (pt) 2006-03-15 2017-12-18 The Brigham And Women`S Hospital Inc Utilização de gelsolina para o tratamento da esclerose múltipla e para o diagnóstico de doenças neurológicas
HUE056086T2 (hu) 2006-03-15 2022-01-28 Brigham & Womens Hospital Inc Gelszolin alkalmazása gyulladásos betegségek diagnosztizálására és kezelésére
PT2250280E (pt) 2008-01-25 2015-03-04 Gen Hospital Corp Utilizações terapêuticas da gelsolina na insuficiência renal
KR101568323B1 (ko) 2014-01-08 2015-11-12 한국원자력의학원 겔솔린을 유효성분으로 포함하는 수지상세포 분화 유도용 조성물 및 이의 분화 유도방법
WO2016033187A1 (en) 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease

Similar Documents

Publication Publication Date Title
JP2011510327A5 (cg-RX-API-DMAC7.html)
Sharp et al. Repeated administration of low-dose cisplatin in mice induces fibrosis
Zhang et al. Leptin mediates the pathogenesis of severe 2009 pandemic influenza A (H1N1) infection associated with cytokine dysregulation in mice with diet-induced obesity
Mishra et al. Nicotine primarily suppresses lung Th2 but not goblet cell and muscle cell responses to allergens
Gao et al. Cytokine and chemokine profiles in lung tissues from fatal cases of 2009 pandemic influenza A (H1N1): role of the host immune response in pathogenesis
Rygiel et al. Lack of CD200 enhances pathological T cell responses during influenza infection
Tu et al. Protective effects of curcumin against hepatic fibrosis induced by carbon tetrachloride: modulation of high-mobility group box 1, Toll-like receptor 4 and 2 expression
Harris et al. Double-stranded RNA induces molecular and inflammatory signatures that are directly relevant to COPD
Hoffman et al. Protein disulfide isomerase–endoplasmic reticulum resident protein 57 regulates allergen-induced airways inflammation, fibrosis, and hyperresponsiveness
WO2011100396A3 (en) Serum clusterin levels in systemic amyloidosis featuring cardiomyopathy
RU2016147122A (ru) Применение серелаксина для снижения gdf-15
JP2017519008A5 (cg-RX-API-DMAC7.html)
JPWO2020032027A5 (cg-RX-API-DMAC7.html)
Parenica et al. Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality
WO2019023181A1 (en) METHODS OF TREATING INFLUENZA-RELATED VIRAL PNEUMONIA
Chuang et al. Anti-CCR3 monoclonal antibody inhibits eosinophil infiltration in Angiostrongylus cantonensis-infected ICR mice
Elsheshtawy et al. Interleukin-17: Could it be a key player in COVID-19 infection severity?
Ganesh et al. Correlation of urinary nephrin with albubinuria to predict early onset of nephropathy in patients with type 2 diabetes mellitus
KR101349198B1 (ko) 항균성 펩티드의 발현을 회복시키기 위한 스핑고실포스포릴콜린 길항제의 용도
KR100953821B1 (ko) 비타민 d 결합 단백질을 이용한 천식 진단 마커 및 천식치료제
JP7412722B2 (ja) 溶血反応により誘発される腎障害の抑制
Yeh et al. Dose‐response relationship of specific allergen exposure‐induced immunological tolerance: a mouse model
Uysal Chronic Obstructive Pulmonary Disease and Metabolic Syndrome
Furusyo et al. High molecular weight form of adiponectin levels of Japanese patients with chronic hepatitis C virus infection
POURMAND et al. Urinary Tamm-Horsfall protein and citrate: a case-control study of inhibitors and promoters of calcium stone formation